Chronic neuropathic pain

Disease ID:222
Name:Chronic neuropathic pain
Associated with:1 target

Targets

Cav2.2
Drugs:  ω-Conotoxin MVIIA (ziconotide)
Side effects:  Cognitive impairment, hallucinations, changes in mood and consciousness
Therapeutic use:  Opioid-unresponsive chronic pain
References:  1-5

Ligands

No ligand related data available for Chronic neuropathic pain

References

Show »

1. Brose WG, Gutlove DP, Luther RR, Bowersox SS, McGuire D. (1997) Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin. J. Pain, 13 (3): 256-9. [PMID:9303259]

2. Mathur VS. (2000) A new pharmacological class of drug for the management of pain. Seminars in Anesthesia, Perioperative Medicine and Pain, 19: 67-75.

3. McGuire D, Bowersox S, Fellmann JD, Luther RR. (1997) Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans. J. Cardiovasc. Pharmacol., 30 (3): 400-3. [PMID:9300326]

4. Penn RD, Paice JA. (2000) Adverse effects associated with the intrathecal administration of ziconotide. Pain, 85 (1-2): 291-6. [PMID:10692631]

5. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR, Mayo M, McGuire D, Ellis D. (2004) Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA, 291 (1): 63-70. [PMID:14709577]